Considering that nOH is due to autonomic dysfunction and often associated with an underlying neurodegenerative disorder, restoring blood pressure (BP) to a normal range may not be a feasible treatment goal. Instead, therapy should focus on symptom improvement in nOH patients.3-6
With the goal of nOH treatment in mind, write “Dispense as written” to ensure your nOH patients receive their medication exactly as prescribed for symptomatic relief.
1. NORTHERA [package insert]. Deerfield, IL: Lundbeck. 2. Data on file. Deerfield, IL: Lundbeck. 3. Freeman R. N Engl J Med. 2008;358(6):615-624. 4. Gibbons CH, Schmidt P, Biaggioni I, et al. J Neurol. 2017;264(8):1567-1582. 5. Freeman R, Wieling W, Axelrod FB, et al. Clin Auton Res. 2011;21(2):69-72. 6. Isaacson SH. Am J Manag Care. 2015;21(suppl 13):s258-s268.
Indications and Usage
NORTHERA (droxidopa) is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson’s disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of NORTHERA should be assessed periodically.
Important Safety Information
WARNING: SUPINE HYPERTENSION
Monitor supine blood pressure prior to and during treatment and more frequently when increasing doses. Elevating the head of the bed lessens the risk of supine hypertension, and blood pressure should be measured in this position. If supine hypertension cannot be managed by elevation of the head of the bed, reduce or discontinue NORTHERA.
WARNINGS AND PRECAUTIONS
USE IN SPECIFIC POPULATIONS
For more information, please see the full Prescribing Information, including Boxed Warning for supine hypertension.